Ozempic® ▼ (semaglutide) in clinical practice

Learning Objectives:

  • To discuss and understand the results of SUSTAIN 7: Ozempic® versus dulaglutide in adults with type 2 diabetes
  • To discuss and understand the results of SUSTAIN 6: cardiovascular outcomes of Ozempic® versus standard of care in
    adults with type 2 diabetes

Prescribing information and adverse event reporting will be available at the meeting.

UK19OZM00356
Date of preparation: Oct 2019

*This session has been organised and funded by Novo Nordisk

Wednesday 30 October 2019

10:50 - 11:10

Workshop

Novo Nordisk Logo

Speakers

Regional Medical Advisor, Novo Nordisk UK